8/25/2005

Dr. Scott Gottlieb was appointed July 29 as one of three deputy commissioners at the FDA, and while Wall Street likes the appointment, some medical experts say they are shocked a Wall Street insider like Gottlieb would be appointed to the job. They question whether his previous job, promoting biotech stocks to investors in a Forbes newsletter, sends the wrong signal at a time when the federal government is more closely looking at ties between Wall Street and doctors researching new drugs. Gottlieb, who doesn't see a conflict, has discontinued the newsletter and says he's cut his ties to Wall Street.

Full Story:
The Seattle Times

Related Summaries